Group 1: Company Strategy and Business Focus - The company is committed to focusing on its core business, emphasizing the "big health" development strategy in pharmaceuticals and healthcare [2] - In pharmaceuticals, the company aims to enhance its integrated development model, covering raw materials, formulations, functional skincare products, and skin health management [2][3] - The healthcare segment includes basic medical care, rehabilitation, and longevity services, creating a comprehensive health ecosystem for customers [2][4] Group 2: Pharmaceutical Business Overview - The pharmaceutical business involves the research, production, and sales of drug formulations and raw materials, with a focus on skin, anti-infection, and anti-tumor products [3] - The company has three raw material production bases, ensuring a stable supply of core products and establishing long-term partnerships with international pharmaceutical companies [3] - The company holds a 13.2% stake in a gene therapy company, making it the third-largest shareholder [3] Group 3: Healthcare Services - The healthcare services include basic medical treatment, rehabilitation, and health management, providing integrated services to improve patient health and longevity [4][5] - The company operates various medical institutions that collaborate on resources, technology, and training to enhance service quality [7] Group 4: Tourism Business - The tourism segment includes operations in scenic area transportation, hotel management, and tourism performances, primarily in five major 5A scenic spots [9] - The company aims to enhance its core competitiveness and improve management levels across its business segments, including tourism [9] Group 5: Financial Performance Projections - For 2025, the company expects a net profit attributable to shareholders between 66 million and 73 million, representing a year-on-year growth of 320.74% to 344.16% [9] - The net profit after excluding non-recurring gains is projected to be between 60 million and 67 million, indicating a growth of 277.59% to 298.31% compared to the previous year [9]

Group 1: Offline Channel Strategy - The company plans to optimize and adjust offline sales channels to improve quality and management capabilities [2] - The transition of distributors from traditional distribution to value-driven sales is a key focus for creating better growth conditions in the offline market [2] - The company aims to expand its offline sales team to lay a talent foundation for long-term business development [2] Group 2: Expansion of Offline Business - The offline business is currently being expanded through two main methods: increasing the number of distributors and direct expansion by the company's sales team targeting large chain terminals [3] - In 2026, the company intends to increase the number of offline partners while ensuring quality [3] Group 3: New Product Development - The company has a robust reserve of new products for 2026, including medical devices and functional skincare products, covering both patch and non-patch forms [3] - Efforts will be made to align the speed and categories of new product launches between online and offline channels [3] Group 4: Performance Guidance - The company does not provide public guidance on offline performance for 2026 but expects a positive start following the optimization and team expansion in 2025 [3]

Group 1: Business Operations and Strategy - In 2025, the company optimized its offline sales channels and improved its management team, leading to enhanced operational capabilities and a solid foundation for 2026 [1] - The sales channels were shifted from traditional distribution to value-driven sales, resulting in a streamlined number of distributors and improved profitability [1] - The offline sales team is divided into three groups: CS and KA channels, professional channels, and OTC channels [1] Group 2: Financial Performance and Projections - Financial data for 2025 is still under audit, with specific figures to be disclosed in the annual report on April 23, 2026 [2] - The offline profit margin is higher than online, with improved profitability due to sales channel optimization [3] - The sales team has grown to over 200 members, reflecting ongoing recruitment efforts [4] Group 3: Product Development and Innovation - The company plans to continue its dual focus on medical devices and functional skincare products, with new product launches expected in various forms including dressings, masks, and creams [5] - Progress is being made on a recombinant type III humanized collagen freeze-dried fiber, which has completed clinical trials and is preparing for submission [6] Group 4: Corporate Governance and Future Plans - The company is considering mergers and acquisitions to enhance R&D capabilities and product offerings, with future updates to be disclosed as per regulatory requirements [7] - The dividend plan for this year has not yet been determined, with an announcement expected on April 23, 2026 [8] - There are ongoing considerations for stock incentive plans, with no current confirmation on implementation [9] - No share reductions have occurred from executives whose restrictions were lifted in February 2025 [9]

Group 1: Online Team and Sales Channels - The company has established operational teams in Shanghai and Hangzhou to enhance online operational efficiency and profitability, focusing on interest e-commerce and shelf e-commerce respectively [2] - All existing sales channels are considered key, with dedicated teams for each channel to deepen exploration and expand new sales channels while improving profitability [3] Group 2: Pricing and Inventory Management - The company's product pricing has remained stable, with improvements in pricing stability due to sales channel optimization [3] - Inventory levels are maintained within a reasonable range, following a sales-driven production principle to ensure timely product supply and minimize operational costs and market risks [3] Group 3: New Product Development - The company has a robust pipeline for new product launches, including medical devices and functional skincare products, with a wide range of formulations and effects [3] - The sales proportion of cosmetic products has increased following the establishment of the Shanghai R&D center, enhancing the product matrix and profitability [3] Group 4: Medical Aesthetics Business - The company is actively advancing its medical aesthetics product layout, with a rich reserve of R&D projects, although future growth as a second growth curve depends on new product output and sales performance [3]

Group 1: Company Performance and Outlook - The company has improved operational efficiency in 2026 due to adjustments in offline sales channels and team enhancements, expressing confidence in delivering satisfactory results for the year [1] - The net profit margins before and after deducting non-recurring losses for 2024 were 32.78% and 29.94% respectively [2] - The company aims to maintain stable gross margins with offline net profit margins expected to be higher than online [2] Group 2: E-commerce Strategy - The company has established e-commerce teams in Shanghai and Hangzhou, focusing on different platforms to enhance operational capabilities [1] - The Shanghai team is responsible for interest-based e-commerce operations, while the Hangzhou team focuses on shelf-based e-commerce [1] Group 3: Product Development and Innovation - The company has accelerated its product launch pace since the establishment of its R&D center in Shanghai, with a focus on both medical devices and functional skincare products [2] - Collaborative R&D efforts with external institutions aim to enhance product development efficiency and adapt to market competition [3] Group 4: Market Position and Pricing Strategy - The company has maintained stable product pricing, with reasonable fluctuations across main channels, and employs promotional strategies to balance sales and pricing stability [3] - There is ongoing consideration for mergers and acquisitions to enhance R&D capabilities and product offerings [3] Group 5: Brand Strategy - The company has engaged sports celebrities as brand ambassadors to strengthen its professional image and explore innovative marketing paths [2]

Group 1: Management and Talent Development - The company has been continuously attracting high-end talent to enhance the management team's structure and capabilities, aiming for sustainable development [1] - The management team is expected to further strengthen talent development initiatives [1] Group 2: Medical Aesthetics Progress - The clinical trial for the "recombinant type III humanized collagen freeze-dried fibers" has been completed, and the company is preparing to submit registration materials [1] Group 3: E-commerce Operations - The e-commerce team is divided into interest e-commerce and shelf e-commerce, with operations based in Shanghai and Hangzhou respectively [2] - The Shanghai team focuses on platforms like Douyin, while the Hangzhou team manages Tmall operations [2] Group 4: Sales Performance and Promotions - The performance during the 3.8 promotional period met expectations, with a focus on daily sales [2] - The company anticipates that the 3.8 promotional activities will positively impact overall performance [2] Group 5: New Product Development - The company plans to continue a dual approach in new product development, focusing on medical devices and functional skincare products [2] - New product forms will include dressings, masks, lotions, creams, and serums, with specifics to be confirmed in 2026 [2] Group 6: Pricing and Cost Management - Product pricing has remained stable, with fluctuations within a reasonable range during promotional periods [2] - The company employs refined operational strategies to control online business costs while enhancing profitability [2] Group 7: Dividend Policy - The dividend proposal for the current year has not yet been determined, with an announcement expected on April 23, 2026 [2]

Product Structure - The company's products are mainly divided into two categories: medical devices and functional skincare products [2] - Non-patch products include various forms such as water, essence, lotion, spray, lyophilized, and single-use essence [2] Non-Patch Product Revenue - The revenue share of non-patch products is continuously increasing following the establishment of the Shanghai R&D center, which has accelerated the speed of new product launches [2] Medical Device Progress - The company is making significant progress with three types of medical devices, including recombinant type III humanized collagen protein lyophilized fibers and dressings, with clinical trials completed for the former [3] - The injectable recombinant type III humanized collagen protein gel is expected to start clinical trials this year [3] Pricing Stability - The pricing situation for the company's products is stable, with overall price differences across channels being controllable [3] - Price fluctuations among mainstream channels remain within a reasonable range, with promotional strategies employed to balance sales and pricing during peak periods [3] Aesthetic Medicine Strategy - The company is strategically entering the aesthetic medicine sector due to its pharmaceutical background, aligning medical device products with existing offerings [3] - The company is monitoring potential acquisition targets in the aesthetic medicine field and will adhere to regulatory disclosure obligations for any developments [3] Dividend Policy - The company has maintained a positive attitude towards returning profits to investors through cash dividends since its listing, although specific dividend amounts will depend on performance and financial planning [3] Equity Incentives - The company has plans for equity incentives as the management team evolves, with intentions to disclose specific details in future announcements [3]

Core Viewpoint - Northeast Pharmaceutical is implementing a "one body, two wings" development strategy to enhance resilience and profitability amid industry challenges and market competition [1] Group 1: Operational Efficiency and Market Strategy - The company is focusing on improving operational quality and market expansion, with a steady increase in core business foundations [2] - By 2025, the company aims for multiple breakthroughs in market layout, with core products achieving historical sales highs and brand influence steadily increasing [2] - The raw materials segment is adapting to market fluctuations by optimizing sales structures and expanding into emerging fields, solidifying its market position [2] Group 2: Production and Quality Control - Northeast Pharmaceutical has achieved cost reduction and efficiency improvements while maintaining a 100% product pass rate for factory output and inspections [3] - The company is enhancing production efficiency through process optimization, equipment upgrades, and management improvements [3] Group 3: Research and Innovation - The company is driving growth through both generic and innovative drugs, with three new generic products approved for market by March 2025 [3] - Ongoing projects in biopharmaceuticals and health products are being developed, including new health-oriented products like functional skincare items [3] Group 4: Strategic Development Framework - The "one body, two wings" strategy aims to strengthen the core business of chemical generics while expanding into biopharmaceuticals and traditional Chinese medicine [4] - The company plans to enhance its competitive advantage and market influence across all business segments, focusing on key product sales and overseas promotion of certified products [4] Group 5: Support Systems for Strategy Implementation - To ensure the effective implementation of the "one body, two wings" strategy, the company is optimizing management mechanisms and enhancing operational efficiency [5] - The focus is on risk management, cost control, and digital transformation to improve overall business quality [5] Group 6: Future Growth Drivers - The core growth drivers for the company include the successful transformation of innovative research results and the internationalization of the raw materials business [6] - Digital management and efficiency improvements are also seen as positive factors for driving performance growth [6]

Core Viewpoint - Northeast Pharmaceutical is implementing a "one body, two wings" development strategy to enhance resilience and profitability amid industry challenges and competition [1][2] Group 1: Operational Efficiency - The company is improving operational quality and efficiency through a "production-sales collaboration, full-chain precision control" system, achieving a 100% product pass rate for the year [2] - Multiple products have received international certifications, enhancing market competitiveness [2] - The company is focusing on core products in the formulation sector, with sales of leading products reaching historical highs and market penetration increasing year-on-year [1][3] Group 2: Research and Innovation - Northeast Pharmaceutical is driving growth through both generic and innovative drugs, with three new generic drug products approved for market by 2025 [2][3] - The company is actively developing biopharmaceuticals and health products, including new health food and skincare items, to diversify its product matrix [2][3] - The company aims to revitalize five old product approvals within the year and accelerate the development of innovative drug projects [3] Group 3: Strategic Development - The "one body, two wings" strategy focuses on strengthening chemical generics while expanding into biomedicine and traditional Chinese medicine [2][4] - The company is enhancing its competitive edge by promoting health products, including cosmetics and food, which are currently in the early stages of market development [3] - A comprehensive support system is being established to ensure the effective implementation of the strategy, including optimizing management mechanisms and enhancing digital transformation [4]

Core Insights - The establishment of the Korea Skin Health Industry Association in Shanghai aims to provide systematic support for Korean companies entering the Chinese market and deepen Sino-Korean industrial cooperation [1] - There is a growing demand among Chinese consumers for skin health management and high-quality products, making the Chinese market highly attractive to the Korean industry [1] - The skin health industry is currently experiencing a dual benefit period from both policy and market perspectives, with Korea having advantages in skin science research and China possessing vast clinical resources and rapid technology transfer capabilities [1] Group 1 - The association will strengthen technology implementation and talent exchange between Korea and China, potentially incubating joint projects among research institutions, hospitals, and companies [5] - The association will serve as a key node for Korean companies to gain insights into the Chinese skin health market trends, policy information, and local partners [5] - The Korean cosmetics export value has been steadily increasing, with China being a major export market, although there has been significant performance differentiation among Korean beauty brands in the domestic market [5] Group 2 - The growth drivers in the domestic market have changed, leading to increased costs and risks for foreign brands operating independently [5] - The Korean government and industry are exploring organized industrial chain collaboration and market resource integration to lower the entry barriers for small and medium-sized brands in China [5] - The "Korean National Pavilion" project, supported by Korean official institutions, is set to launch in February 2026 in Hainan Free Trade Port, aiming to serve as a permanent platform for high-quality Korean beauty products to systematically enter the Chinese market [5]